Aberrant DNA methylation constitutes a well-established epigenetic marker for breast cancer. Changes in methylation early in cancer development may be clinically relevant for cancer detection and prognosis-based therapeutic decisions. In the present study, a combination of methyl-CpG immunoprecipitation (MCIp) and human CpG island (CGI) arrays was applied to compare genome-wide DNA methylation profiles in 10 low-grade in situ and invasive breast cancers against 10 normal breast samples. In total, 214 CGIs were found to be hypermethylated in >6 of 10 tumors. Functional term enrichment analyses revealed an overrepresentation of homeobox genes and genes involved in transcription and regulation of transcription. Significant hypermethylation of 11 selected genes in tumor vs. normal tissue was validated in two independent sample sets (45 tumors and 11 controls, 43 tumors and 8 controls) using quantitative EpiTyper technology. In tumors, median methylation levels of BCAN, HOXD1, KCTD8, KLF11, NXPH1, POU4F1, SIM1, and TCF7L1 were >30% higher than in normal samples, representing potential biomarkers for tumor diagnosis. Using the 90th percentile of methylation levels in normal tissue as cutoff value, 62-92% of in situ samples (n‫,)31؍‬ 72-97% of invasive samples from the first validation set (n‫,)23؍‬ and 86 -100% of invasive samples from the second validation set (n‫)34؍‬ were classified as hypermethylated. Hypermethylation of KLF11 and SIM1 might also be associated with increased risk of developing metastases. In summary, early methylation changes are frequent in the low-grade pathway of breast cancer and may be useful in the development of differential diagnostic and possibly also prognostic markers.-Faryna, M., Konermann, C., Aulmann, S., Bermejo, J. L., Brugger, M., Diederichs, S., Rom, J., Weichenhan, D., Claus, R., Rehli, M., Schirmacher, P., Sinn, H.-P., Plass, C., Gerhauser, C. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 26, 000 -000 (2012). www.fasebj.org
therapy in breast cancer is early detection, ideally at a preinvasive stage. Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) are examples of such premalignant lesions. Whereas patients with metastatic breast cancer have an age-standardized 5-yr survival rate of only 21%, detection at an earlier stage increases the rate to 80% for localized invasive cancer and to 98% for in situ carcinoma (2) . Breast cancer is currently classified into multiple histological phenotypes; the most frequent is invasive ductal carcinoma (IDC; 50 -80% of all cases), invasive lobular carcinoma (ILC; 5-15%), tubular carcinoma (TUB, Ͻ2%), and others (3) . The heterogeneity of breast cancer contributes to the challenge of defining prognosis and adjusting therapy. Expression levels of estrogen receptor (ER) and progesterone receptor (PR) positively correlate with disease-free and overall survival and provide prognostic information (4) . Also, gene expression profiling has resulted in the definition of specific molecular signatures associated with disease outcome (5, 6) , but predicting tumor progression in an individual case is still problematic. To improve early recognition and treatment of breast cancer, new markers for detection and prognosis need to be identified.
Disease-associated epigenetic modifications such as altered histone modification patterns and aberrant DNA methylation hold promise for developing such markers. Over the past 2 decades, numerous studies have highlighted the contribution of epigenetic alterations to the malignant phenotype in various cancer types. In particular, hypermethylation of promoter CpG islands is a well-established mark for transcriptional inactivation and is often associated with downregulation of tumor suppressor genes, such as p16, BRCA1, E-cadherin, DAPK1, and APC (7) (8) (9) . This type of aberrant DNA methylation is, therefore, recognized as one of the key events leading to tumor initiation and progression (10) . In addition, due to the early occurrence and stability of DNA methylation, it has a great potential to become a marker for early cancer detection and prognosis.
Several previous methylation studies have analyzed candidate genes for tumor-specific hypermethylation in breast cancer that are involved in cell cycle control, apoptosis, and DNA repair, including RASSF1A, HIN1, and Cyclin D2 (reviewed in ref. 11) . Starting from the study of Ordway et al. (12) , the introduction of genome-wide methylation screening methods to breast cancer research has provided a broader overview of the breast cancer methylation landscape. Recent genome-wide breast cancer methylation studies (summary in Supplemental Table S1 , reviewed in refs. 13, 14) have demonstrated that aberrant DNA methylation of specific loci is already well established at the DCIS stage and is further maintained in invasive cancers and metastases (15, 16) . Moreover, distinct DNA methylation patterns have been associated with hormone receptor status (16 -19) , expression subtypes (20 -23), mutation status (24) , and disease progression (16, 18, 19, 23, 25) . So far, studies investigating association of methylation with metastatic behavior have reported differing results (18, 19, 25) . Most of these studies were based on Illumina Infinium HumanMethylation27 and Illumina Golden Gate Cancer Panel I methylation measurements (Illumina, Inc., San Diego, CA, USA), which interrogated on average 2 CpG loci for a selected number of gene promoters (14, 475 promoters for Illumina 27k and 807 promoters for Illumina Golden Gate).
In the present study, we have applied a multistage strategy to identify novel methylation biomarkers in low-grade breast cancer, especially in ER-positive and/or PR-positive cases. In the screening stage, we have combined methyl-CpG immunoprecipitation (MCIp) with human CpG island (CGI) arrays (26, 27) . This approach has allowed not only identification of hypermethylated genes but also definition of areas within their promoters that display the most prominent methylation changes compared to normal breast tissue. Subsequently, we have validated and quantified aberrant methylation in two independent sample sets containing various histological subtypes and grades of ER-and/or PR-positive breast cancer using EpiTyper MassArray technology and have correlated methylation levels with clinical parameters.
MATERIALS AND METHODS

Patient samples and cell lines
Breast tumor tissue and control samples were obtained from the Institute of Pathology of the University Hospital, Tissue Bank of the National Center of Tumor Diseases (Heidelberg, Germany). All patients signed a written consent and authorization for use of biological specimens. Sample collection was approved by the ethics committee of the University of Heidelberg. The screening sample set consisted of 2 low-grade preinvasive lesions, 8 low-grade invasive tumors, and 10 normal breast tissue samples (one of them from an affected patient). Validation sample sets 1 (45 tumors and 11 controls) and 2 (43 tumors and 8 controls) were derived from macrodissected tissues. Clinical and pathological data are summarized in Table 1 . Normal breast tissue samples were obtained from morphologically normal tissue located Ն3 cm away from the tumor (screening set and validation set 1) or from reduction mammoplasty tissue (validation set 2) provided by the Department of Gynecology and Obstetrics, University Hospital Heidelberg.
The MCF7 cell line was provided by the cell line repository of the German Cancer Research Center (H. Löhrke, DKFZ Tumorbank, Heidelberg, Germany) and was maintained in Dulbecco's modified Eagle medium (Gibco; Invitrogen; Life Technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS; PAA, Pasching, Austria) and 1% streptomycin/penicillin (Gibco; Invitrogen). T47D cells were derived from American Type Culture Collection (ATCC; Manassas, VA, USA) and were propagated in RPMI 1640 medium (PAA) supplemented with 10% FBS (PAA). Identity of cell lines was verified by single tandem repeat typing.
DNA isolation
Genomic DNA (gDNA) extraction from the screening set of tissues was performed according to the Tissue Protocol of the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). After incubation with AL buffer, an additional centrifugation step (2000 g, 10 min) was added for fat removal. For DNA extraction from tissues of validation set 1, formalin-fixed paraffin-embedded (FFPE) slides were deparaffinized by xylene, rehydrated using graded alcohols, and subjected to tissue microdissection using glass capillaries. Next, the samples were incubated for 16 h with proteinase K (100 g/ml final concentration), then heat inactivated and directly used for bisulfite conversion. DNA from validation set 2 was isolated with TRIzol reagent (Invitrogen) according to the manufacturer's protocol. DNA from cell lines was extracted 
MCIp, sample labeling, and array hybridization
Genes differentially methylated between tumor and normal tissue were detected by a combination of methyl-CpG enrichment technique and human CGI microarrays (Agilent Technologies, Santa Clara, CA, USA), similar to formerly applied approaches (15, 26, 28) . MCIp experiments were performed as described previously (26, 27) with minor modifications. Briefly, 2 g gDNA was fragmented by ultrasonication and immunoprecipitated with 60 g MBD2-Fc protein. Unbound DNA was recovered by centrifugation. Bound DNA was eluted twice with buffers containing increasing NaCl concentrations (400, 500, 550, 600, and 1000 mM NaCl). Desalted eluates were controlled for enrichment of methylated DNA by quantitative PCR (qPCR) using the QuantiTect SYBR Green PCR kit (Qiagen) with primers targeting the imprinted SNRPN gene ( Table 2 ). For differential labeling with Alexa Fluor 5 and Alexa Fluor 3 (BioPrime Total Genomic Labeling System; Invitrogen), 600 and 1000 mM NaCl fractions were combined. Tumor and normal samples were paired randomly (except for one case with available matching normal tissue) and hybridized to human CGI microarrays (Agilent Technologies) using the Oligo aCGH Hybridization Kit 
Microarray data analysis and functional gene enrichment analysis
Microarray images were processed with Feature Extraction Software 10.5 (Agilent Technologies) according to the CGH_105_Dec08 protocol. Array data were corrected for GC content as reported previously (29) . Using the Tibco Spotfire 2.2.0 software (Spotfire, Gothenburg, Sweden) and Excel scripts (Microsoft, Redmond, WA, USA), hypermethylated CGIs were identified. Probes most frequently detected as positive within a CGI, designated as differentially methylated regions (DMRs), were selected, and their representation in the various tumor samples was determined. The genes that were associated with 214 CGIs and hypermethylated in Ն6 of 10 arrays (reported in Supplemental Table S2 ) were used as input for the DAVID Functional Annotation tool (30, 31) . Of the gene annotations analyzed on the Agilent human CGI array background, 165 were recognized, with the following parameters: similarity term overlap 4, similarity threshold 0.7, initial group membership 5, final group membership 5, and multilinkage threshold 0.5. The data discussed in this publication have been deposited in the U.S. National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (32) and are accessible through GEO Series accession number GSE35263.
Quantitative methylation analysis
Genomic DNA was subjected to sodium bisulfite treatment using the EZ methylation kit (Zymo Research, Orange, CA, USA) according to the manufacturer's instructions. Quantitative DNA methylation analysis was performed by MassArray EpiTyper technology (Sequenom, San Diego, CA, USA) as described previously (33, 34) . Data were corrected using DNA methylation standards (0, 20, 40, 60, 80, and 100% methylated genomic DNA). Primer sequences are listed in Table 3 . The location of EpiTyper amplicons relative to respective genes is depicted in Supplemental Fig. S2 .
2=-Deoxy-5-azacytidine (DAC) treatment
Breast cancer cell lines were treated for 96 h (T47D) or 72 h (MCF7) with 0.5 or 1 M DAC (decitabine; Sigma-Aldrich, Munich, Germany) dissolved in dimethyl sulfoxide (DMSO), respectively. Medium containing DAC or DMSO as solvent control (0.005 and 0.01% final DMSO concentration for T47D and MCF7, respectively) was renewed every 24 h. Each experiment was independently repeated 3 times.
RNA isolation, reverse transcription, and qPCR analysis
RNA was isolated with TRIzol (Invitrogen; MCF7) and RNeasy Mini Kit (Qiagen; T47D), including an additional DNase treatment (RNase-Free DNase Set; Qiagen). M-MLV Reverse Transcriptase set (Promega, Madison, WI, USA) was used for reverse transcription. Real-time qPCR analysis was performed with the QuantiTect SYBR Green PCR kit using a program of 15 min at 95°C followed by 45 cycles of 10 s at 95°C, 15 s at 60°C, and 20 s at 72°C on a Roche Lightcycler 480 Real-Time PCR System (Roche, Mannheim, Germany). ␤-Actin (ACTB) was used as a housekeeping gene. Primer sequences are available in Table 2 .
Tissue microarray protein expression analysis
A tissue microarray (TMA) was assembled from the same collection of FFPE donor blocks as used for validation sample set 1 and contained 5 normal tissues, 13 in situ tumors, and 32 invasive lesions. For each sample, two representative tissue cores 0.6 mm in diameter were obtained and combined in one TMA using a semiautomated array system (Beecher Instruments, Silver Spring, MD, USA). Immunostains were performed on 1-m sections of the TMAs after heat pretreatment (1 mM EDTA, pH 9) using a polymer-based detection system (Zytomed, Berlin, Germany). Primary antibodies against neurexophilin 1 (NXPH1; ProteinTech Group, Chicago, IL, USA), tachykinin precursor 1 (TAC1; Sigma, St. Louis, MO, USA), and brevican (BCAN; Sigma) were diluted 1:100, 1:25, and 1:30, respectively. For NXPH1 and TAC1, 6 additional normal tissues were stained separately according to the same protocol.
Statistical analyses
The non-normal distribution of methylation and expression data and the relatively small number of observations for some experiments motivated the use of nonparametric statistics. Tumor hypermethylation was investigated by Mann-Whitney U tests and quantified by median differences with 1-sided 95% confidence intervals (CIs). The correlation among methylation levels in neighboring CpG units and the relationship between methylation and clinical characteristics was measured by Spearman's rank correlation . Kruskal-Wallis tests were used to evaluate associations between methylation and expression.
Metastasis-free survival was calculated from the date of operation to detection of metastasis. Patients who did not experience metastasis by last contact were classified as censored. The median follow-up time of patients with metastasis (nϭ11) was 6 yr. The association between methylation and risk of metastasis was assessed by log-rank tests and represented by Kaplan-Meier plots. To account for the influence of established prognostic factors, hazard ratios (HRs) and 95% CIs were adjusted in a multivariate Cox proportional hazard regression. To quantify the accuracy of methylation as diagnostic marker, the area under the receiver operating characteristic (ROC) curve was estimated with 95% CIs based on the Mann-Whitney U statistic. Amplicon-wise estimates were obtained by bootstrapping, taking into account the intrasample correlation of methylation values (10,000 bootstrap samples). The reported P values are not corrected for multiplicity. The focus on amplicon-wise instead of single CpG-unit effects should alleviate the multiplicity problem, and together with the investigation of independent sample sets increase the likelihood of external replication of our findings.
RESULTS
Genome-wide methylation analyses identify homeobox and transcriptional regulatory genes as frequently hypermethylated in breast cancer
We applied a combination of MCIp and human CGI microarrays to identify aberrant DNA hypermethylation in 8 low-grade invasive carcinomas and 2 preinvasive in situ tumors, mostly ER-and/or PR-positive, against 10 normal breast tissues. The analysis yielded a list of 214 CGIs, which were detected as hypermethylated in Ն6 of 10 arrays (Supplemental Table S2 ). The CGI associated with TAC1 was the only hotspot of aberrant tumor hypermethylation common for all 10 samples. Twelve CGIs were identified as hypermethylated in 9 samples, followed by 22, 62, and 117 CGIs hypermethylated in 8, 7, and 6 samples, respectively. Functional annotation analysis using DAVID software (30, 31) revealed a significant overrepresentation of homeobox genes (enrichment score 21.8) and genes involved in transcription and regulation of transcription among hypermethylated genes (16.8) . Further functional terms included cell morphogenesis and neuron development (5.8), positive regulation of transcription (5.5), regula- 
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tion of neurogenesis (4.3), negative regulation of biosynthetic processes (4.0), cadherins (3.3), and cell migration and motility (2.4) (Supplemental Table S3 ). Analysis of the relative location of the CGIs indicated that 53% coincided with gene promoters (defined as a 5-kb region upstream of a gene transcription start site, according to Agilent probe annotations) and 62% overlapped with gene bodies (defined as the whole gene from the transcription start site to the end of the transcript). This observation supports a possible role of methylation in epigenetic gene silencing of the associated genes.
Quantitative EpiTyper methylation analysis verifies genome-wide methylation screen
To validate our microarray results, we selected a series of candidate genes: BCAN, homoeobox D1 (HOXD1), potassium channel tetramerization domain containing 8 (KCTD8), Kruppel-like factor 11 (KLF11), NXPH1, POU class 4 homeobox 1 (POU4F1), ryanodine receptor 2 (RYR2), single-minded homologue 1 (SIM1), TAC1, and transcription factor 7-like 1 (TCF7L1) for quantitative EpiTyper analysis using the initial sample collection. Locations of most common DMRs covered by EpiTyper amplicons are indicated in Supplemental Fig. S2 . Gene selection was based on the extent and frequency of methylation changes and proximity to gene promoter, as well as existence of specific antibodies. In addition, protocadherin 10 (PCDH10) was chosen since it has been previously reported as a tumor suppressor gene (35) (36) (37) .
EpiTyper analysis confirmed the presence of tumor hypermethylation in the analyzed DMRs, with each DMR being represented by 3 to 8 CpG units (single CpG sites or groups of 2 or more CpG sites; Fig. 1 
DAC treatment leads to demethylation and gene reexpression in two breast cancer cell lines
Next, we tested whether hypermethylation of the 11 candidate genes was associated with gene silencing. treated the ER-positive breast cancer cell lines T47D and MCF7 with optimized concentrations of DAC (Fig. 2) . EpiTyper analysis revealed elevated median methylation levels in the range of 0.3 to 1.0 (30 to 100%) for all candidate DMRs in both cell lines. DAC treatment reduced methylation of DMRs by 5 to 50% compared to solvent control samples. Accordingly, the majority of the genes showed either an increase in expression (BCAN, HOXD1, NXPH1, and PCDH10) or a change from no expression in the control samples to detectable mRNA levels in DAC-treated samples (KCTD8, POU4F1, RYR2, SIM1, and TAC1).
Exceptions were KLF11 and TCF7L1, for which expression was already high in both cell lines before DAC treatment and was not further increased following demethylation. These results were consistent between both investigated cell lines and indicated that methylation indeed contributes to regulation of expression of most of the candidate genes.
Candidate genes are early and frequently hypermethylated in breast carcinomas
To determine whether the selected genes are commonly targeted by hypermethylation in breast cancer, we quantified methylation levels in a larger sample set (validation set 1) consisting of 45 macrodissected low-grade, ER-positive, and/or PR-positive in situ and invasive carcinomas of various histological subtypes and 11 normal tissues (patient characteristics in Table 1 ). Consistent with quantitative methylation data obtained for the screening sample set, methylation was increased in both in situ and invasive cancers compared to normal samples (Fig. 3, top  panel) . No statistically significant methylation differences were found among cancer subtypes (IDC, ILC, and TUB; data not shown). Notably, 9 genes were already significantly hypermethylated in in situ samples compared to normal tissue (Fig. 3 , bottom panel, and Table 4 ). Methylation levels in the in situ samples were almost as high as in invasive tumors and showed a similar pattern for the majority of the genes. These data suggest that the investigated genes were hypermethylated in early stages of tumor development and hypermethylation was maintained during breast carcinogenesis. Median methylation differences between invasive breast cancer and normal samples were highest for TCF7L1 (0.58), NXPH1 (0.54), BCAN (0.51), and KCTD8 (0.49).
To assess the frequency of hypermethylated samples in validation set 1, we defined gene-specific thresholds based on the 90th methylation percentile in normal samples (Table 4) . KCTD8, KLF11, NXPH1, POU4F1, and SIM1 (respective thresholds: 0.03, 0.30, 0.39, 0.16, and 0.35) were identified as the most commonly hypermethylated among our candidate genes in invasive tumors, with hypermethylation frequencies ranging from 91 to 97%. These genes were also hypermethylated in 62 to 92% of the in situ samples. We have thus validated 11 genes as aberrantly methylated in both in situ and invasive carcinomas in comparison to normal breast tissue. Our results indicate that the investigated DMRs are frequently hypermethylated already in early stages of breast cancer.
NXPH1 hypermethylation is associated with decreased protein expression
Using TMAs representing samples of validation sample set 1, we examined whether methylation of selected DMRs affected protein expression levels of the associated genes. Commercially available antibodies against BCAN, NXPH1, and TAC1 showed consistent and specific immunohistochemical staining. Staining intensity was interpreted semiquantitatively at a score scale of 0 to 3. Epithelial cells in normal samples (Fig. 4A-C) demonstrate strong NXPH1 staining (score 3); one of the invasive tumors (Fig. 4D) shows moderate NXPH1-staining (score 2), while both other invasive tumor samples (Fig. 4E, F) lack detectable NXPH1-expression (score 0). Staining for BCAN, NXPH1 and TAC1 was less frequent in tumor samples than normal tissues ( Table 5) . For example, NXPH1 protein was detectable 
Hypermethylation is confirmed in low-and high-grade breast carcinomas
We quantitatively analyzed methylation levels in a second independent sample set (validation set 2). This set comprised 43 IDC ER-and/or PR-positive cases and included both low-and high-grade tumor samples (patient characteristics in Table 1 ). Quantitative methylation analysis confirmed methylation differences between invasive tumors and normal samples ( Table 6 and Supplemental Fig. S1 ). Using the same thresholds as in Table 4 , BCAN, KCTD8, and SIM1 hypermethylation correctly identified 93, 100, and 95% of the invasive carcinomas, respectively. To evaluate the diagnostic accuracy of methylation in the investigated genes, we performed ROC curve analyses exemplarily for BCAN, KCTD8, KLF11, NXPH1, and SIM1 ( Table 7) . In validation set 1, area under curve (AUC) estimates for ROC were in the range of 0.82-0.88 for in situ carcinomas and 0.88 -0.96 for invasive breast cancers. High discriminating power was confirmed for invasive cancers in validation set 2, with AUC estimates of 0.91-0.98.
The combined study of both validation sample sets had 90% power to detect a hypermethylation difference Ͼ 0.34. This was determined by multiplying the combined sample size for a 2-sample t test [1-sided, ␣ϭ0.0045 (0.05 divided by 11 genes), 88 tumor, and 19 normal samples, common sd of 0.3] by the asymptotic relative efficiency for a Mann-Whitney U test under normality (0.95). 
Hypermethylation of selected genes correlates with tumor characteristics and increased risk of metastasis
We further explored potential relationships between hypermethylation and tumor characteristics for the invasive tumor groups. We found an association between tumor grade and BCAN methylation in both validation sets (P ϭ0.04 for validation set 1; Pϭ0.01 for validation set 2). In addition, NXPH1 methylation positively correlated with tumor proliferation (determined by MIB or Ki-67 staining), as reflected by Spearman's rank correlation ϭ 0.32 (Pϭ0.02) in validation set 1 and ϭ 0.24 (Pϭ0.13) in validation set 2. KCTD8 methylation and tumor proliferation were correlated with ϭ 0.24 (Pϭ0.15) in validation set 1, and ϭ 0.34 (Pϭ0.01) in validation set 2. BCAN, HOXD1, and SIM1 methylation levels positively correlated with EZH2 mRNA expression. We were interested in the prognostic relevance of aberrant methylation in the selected DMRs and investigated whether methylation levels were associated with an increased risk to develop metastases using data from validation set 2 with clinical follow-up available. A weak association between methylation and risk of metastasis was found for KLF11 (Pϭ0.06) and SIM1 (Pϭ0.04). Survival analyses indicated that a 0.1 (10%) increase in KLF11 methylation increases the risk of metastasis by 37% to 1.37 (95% CI: 0.99 -2.28), while for SIM1, the increase in risk was 29% to 1.29 (95% CI: 1.02-1.88). Metastasis-free survival also correlated with the expression of tumor proliferation marker Ki-67 in the investigated patient collective (Pϭ0.01). After adjustment for Ki-67 staining, the HR associated with a 10% increase in methylation was 1.38 for KLF11 (95% CI: 0.97-2.59) and 1.25 for SIM1 (95% CI: 0.96 -1.91). These data suggest that methylation levels of both genes may have prognostic significance.
In addition to HRs based on amplicon-wise methylation, we illustrate the potential prognostic value of single CpG-unit methylation for KLF11 using a KaplanMeier plot (Fig. 5A and Table 8 ). Taking CpG unit 5 of KLF11 as an example, the patient cohort was divided into 2 groups according to median methylation. This methylation value was selected because it divides the sample set into 2 subsets of similar size with 21 and 22 women. Two metastasis events occurred in the group with methylation Ͻ 0.62, whereas 9 metastasis events were detected in the remaining patients (Pϭ0.009; log-rank test). Figure 5B represents the estimated correlations among methylation values in neighboring CpG-units of KLF11. This figure has a descriptive purpose similar to linkage disequilibrium plots in association studies. The plot reflects a strong within-amplicon dependence of methylation values among CpGunits. The lowest estimated correlation amounted 0.82 and the highest was 0.97.
DISCUSSION
Genome-wide methylation screen and validation of hypermethylation as diagnostic marker
In the present study, we aimed at identifying genes hypermethylated in breast cancer as potential biomarkers for detection and prognosis. We primarily focused on the biology of low-grade ER-and/or PR-positive breast cancer using samples from various histological subtypes and stages, including DCIS, IDC, TUB, LCIS, and ILC. Our array-based genome-wide methylation screen identified Ͼ200 hypermethylated CGIs that may constitute novel targets for biomarker discovery and harbor pathological relevance. In concordance with earlier reports (15, 18, 39, 40) , homeobox genes and protocadherins were enriched among the hypermethylated genes. Our list of 214 CGIs contains 197 unique gene names. Among them, 21 genes overlapped with a n ϭ number of analyzed samples. ⌬ Methylation indicates median methylation difference between groups, with 1-sided 95% CI in parenthesis. Methylation was measured on a 0 (0%) to 1 (100%) scale. P values are for a median hypermethylation Ͻ 0.1 (10%). Threshold was used to calculate frequencies of hypermethylation in tumors. Threshold for each amplicon was defined as the 90th percentile of median methylation levels for combined normal tissues from validation set 1 and validation set 2. Frequency indicates percentage of samples exceeding the threshold value.
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list of 79 hypermethylated genes identified in the study of Tommasi et al. (15) . Similarly, a set of 21 genes overlapped with 264 hypermethylated genes provided by Hill et al. (19) , whereas 60 genes were identified as recurrently hypermethylated in comparison with 852 hypermethylated genes reported by Van der Auwera et al. (20) . These parallels between different studies using various platforms (see Supplemental Table S1 ) underscore the universal character of the observed hypermethylation events and support their applicability as detection biomarkers. We selected 11 candidates for quantitative methylation analysis and validated hypermethylation at representative DMRs in the screening sample set and in two independent validation sample sets. Previous single-gene studies on genes such as 14-3-3, RASSF1A, HIN-1, GSTP1 , APC, CDH1, CTNNB1, and others (41) (42) (43) (44) (45) (46) (47) (48) (49) suggest that methylation changes occur early in the development of breast cancer and are frequent already at the in situ stage. From our 11 candidate genes, TAC1, NXPH1, and KLF11 were identified as hypermethylated in DCIS in an earlier genomewide screen (15) . In agreement with these studies, we Immunostains were performed using alkaline phosphatase and fast red (red); hematoxylin (blue) was used for counterstaining. Table 5 shows proportion of samples staining positively for BCAN, NXPH1 and TAC1, presented as percentage values. G) Median methylation of the NXPH1 amplicon was plotted against staining intensity for all samples (normal, in situ and invasive) analyzed with NXPH1 antibody. **P Ͻ 0.01; Kruskal-Wallis test. confirmed frequent hypermethylation of all the candidate genes already at the in situ stage (frequency ranging from 46 to 92%). We did not detect significant differences in methylation levels between in situ carcinomas and invasive carcinomas although the methylation frequency was ϳ2-29% lower in in situ cases compared to invasive tumors (see Fig. 3 and Table 4 ). Methylation levels were not different between distinct tumor subtypes. Our data suggest that at least some targets of aberrant methylation are common for many histological subtypes of ER-and/or PR-positive breast cancer and are frequently hypermethylated in both early and late stages of breast cancer. Hypermethylation of these genes may therefore be regarded as an attractive cancer diagnostic biomarker. The predictive value of our study is restricted by the limited number of in situ samples and the fact that some in situ cases were derived from samples with adjacent invasive tumors. However, especially early detection of in situ stage tumors may constitute a significant clinical advantage. Present results may help to design future studies to validate current findings. Our estimated ROC AUC estimates for BCAN, KCTD8, KLF11, NXPH1 and SIM1 methylation in in situ carcinoma were 0.85, 0.84, 0.88, 0.83, and 0.82 (see Table 7 ), respectively, which indicates the high diagnostic value of methylation at these genes.
Hypermethylation as a potential prognostic marker for metastasis risk?
In earlier studies, high methylation of single candidate genes or groups of genes identified in genome-wide screens was associated with poor overall survival (18), occurrence of distant metastasis (20) , or tumor relapse (19) . Here, hypermethylation of two candidate genes (KLF11 and SIM1) was weakly associated with an elevated risk of developing metastases, although the observed prognostic value may be dependent on tumor proliferation. Thus it is important to further assess the prognostic relevance of these findings using a larger sample collection.
Specific function of candidate genes in breast carcinogenesis?
What remains to be answered is whether our identified candidate genes, in addition to serving as potential biomarkers, might have tumor suppressor properties or specific functions in mammary development or tissue differentiation that are lost during breast carcinogenesis as a result of hypermethylation. In cell culture experiments, hypermethylation of these genes was in general associated with gene silencing that was reversed n ϭ number of analyzed samples. ⌬ Methylation indicates median methylation difference between groups, with 1-sided 95% CI in parenthesis. Methylation was measured on a 0 (0%) to 1 (100%) scale. P values are for a median hypermethylation Ͻ 0.1 (10%). Threshold was used to calculate frequencies of hypermethylation in tumors. Threshold for each amplicon was defined as the 90th percentile of median methylation levels for combined normal tissues from validation set 1 and validation set 2. Frequency indicates percentage of samples exceeding the threshold value. Values in parentheses represent 95% CIs.
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after DAC treatment (see Fig. 2 ). DAC treatment may lead to gene reexpression either through direct demethylation or through an indirect effect as the result of reexpression or activation of transcription factors, etc. Despite reduced DNA methylation, TCF7L1 and KLF11 mRNA levels were not up-regulated following DAC treatment. In comparison with the reexpressed genes, these genes had already high basal expression in the investigated cell lines before DAC treatment. In both cases, the genomic region investigated by EpiTyper analyses was located outside of the canonical promoter, indicating that this most differentially methylated region might not contribute to the regulation of expression of these genes.
Further supporting the inverse link between methylation and gene expression, protein expression of BCAN, NXPH1, and TAC1 was reduced in tumor samples compared to normal tissue as indicated by immunohistochemical staining of TMA sections (see Fig. 4 ). According to the NCBI gene database, the primary function of BCAN, HOXD1, KCTD8, NXPH1, PCDH10, POU4F1, SIM1, and TAC1 involves developmental and neural processes. PCDH10 has putative tumor suppressor function in nasopharyngeal, esophageal, gastric and other cancers (36, 50) , whereas RYR2 is overexpressed in malignant melanomas and derived cell lines (51) . So far, no tumor-related specific functions of our candidate genes in breast development have been established, but it is possible that loss of expression of these genes plays a yet-unknown role in breast carcinogenesis.
Widschwendter et al. (52) and Ohm et al. (53) postulated an alternative hypothesis addressing the function of genes hypermethylated in cancer. They suggest that the methylation profile could reflect a stem cell origin of the tumor. In stem cells, sets of developmental genes are reversibly silenced by bivalent chromatin marks of activating histone 3 lysine 4 dimethylation (H3K4me2) and inactivating histone 3 lysine 27 trimethylation (H3K27me3). During carcinogenesis, the bivalent chromatin becomes methylated and thus locked in an inactive state. Whether this process is a bystander effect of tumorigenesis or whether it may actively contribute to tumor development (e.g., by conserving the stem cell-like phenotype through permanent inactivation of differentiation programs) is still unclear. The fact that the top 214 aberrantly methylated CGIs identified in our study are significantly enriched for homeobox genes might provide further support for this model. Homeobox genes are known to be frequent targets of polycomb group (PcG) proteins in embryonic stem cells (ESCs) (54) and these targets, in turn, tend to be de novo methylated in cancer (55, 56) . EZH2 is a PcG protein that has been reported to be overexpressed in breast cancer (57) . This observation was confirmed in a subset of samples of validation set 2 with significant increase of EZH2 mRNA levels in tumor samples compared to normal tissues (Pϭ0.031; t test). BCAN, HOXD1, and SIM1 are known PcG protein targets in ESCs (54) , and their methylation levels correlated with EZH2 expression. This may point to a functional link between EZH2 and gene silencing (58), but does not exclude independent mechanisms (59) .
In summary, we have identified aberrant methylation of multiple genomic regions. These changes are frequent in early stages of breast cancer, as well as in its most common subtypes. They are also detected in high-grade tumors and might serve as biomarkers for the detection of breast cancer. Fig. S1 ). Patients in validation set 2 were divided into 2 groups according to median methylation at CpG unit 5 (0.62), separating the sample set into 2 subgroups of equal size. Groups are represented by black and gray lines for methylation levels Ͻ 0.62 and Ն 0.62, respectively. Table 8 summarizes numbers of patients followed over time for each group. B) Spearman's rank correlations among methylation values of single CpG units within the KLF11 amplicon were calculated based on methylation data from validation sample set 2 to illustrate the within amplicon dependence of methylation values. Color code ranges from white (ϭϪ1) to dark gray (ϭ1). The degree of methylation of invasive ductal carcinomas (IDC), normal tissues (N) and methylation standard (STD) was assessed by EpiTYPER analysis.
Each row represents a sample and each column depicts a CpG unit (single CpG or a group of CpGs). The degree of methylation is indicated by a color gradient from yellow (not methylated) to red (fully methylated). Grey color represents missing values. Grade and type of respective tumors are represented by the color coding on the left side of the heatmap. Asterisk marks the CpG unit corresponding to Kaplan-Meier curve presented in Figure 5 .
The lower panel depicts median methylation differences with one-sided 95% confidence interval between tumor samples and normal tissues for each CpG unit. In case that no gene was associated, the exact genomic location of hypermethylated region is given. The detailed information on location of CGIs relative to genes, genomic location of DMRs and their representation in the various tumor samples is available from the authors. A, B, C -genes overlapping with gene lists provided in references (15) , (19) and (20), respectively.
